Protection against alcohol-induced gastric mucosal injury by geranylgeranylacetone: effect of indomethacin.
The mechanism of gastric mucosal protection by an antiulcer agent, geranylgeranylacetone (GGA), against ethanol-induced injury was investigated. The experiments were conducted with groups of rats with and without intraperitoneal indomethacin pretreatment. Animals received intragastrically either a dose of GGA (200 mg/kg) or a vehicle, followed 30 min later by 1 ml of absolute ethanol. The rats were sacrificed after 30 min and the gastric mucosa was subjected to macroscopic and histologic assessment and the measurements of adherent mucus, its dimension and chemical composition. In the absence of GGA, ethanol produced advanced macroscopic necrosis (greater than 38%) and the extensive necrotic lesions were visible upon histologic examination. Pretreatment with GGA significantly reduced (p less than 0.001) the extent and depth of mucosal necrotic lesions caused by ethanol, and this protection was not thwarted by indomethacin. Evaluation of the adherent mucus and its dimension by Alcian blue uptake and inverted microscope technique revealed that GGA was also capable of preventing the untoward effect of indomethacin on the adherent gastric mucus gel and its thickness. Results of chemical analyses established that in the absence of GGA indomethacin caused an increase in mucus protein (15%) and a decrease in its covalently bound fatty acids (67%) and lipids (36%). The decrease in lipids was particularly reflected in the content of phospholipids. Indomethacin, however, had no apparent effect on the composition of gastric mucus elaborated in the presence of GGA. The results suggest that gastric mucosal protective action of GGA is not mediated by endogenous prostaglandins but rather appears to involve the metabolism of mucosal lipids.
Bilski
J
J
Research Center, New Jersey Dental School, University of Medicine and Dentistry of New Jersey, Newark.
Murty
V L
VL
Nadziejko
C
C
Sarosiek
J
J
Aono
M
M
Moriga
M
M
Slomiany
A
A
Slomiany
B L
BL
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002241:Carbohydrates / Q000032:analysis; D004224:Diterpenes / Q000494:pharmacology*; D000431:Ethanol / Q000633:toxicity*; D005227:Fatty Acids / Q000032:analysis; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D007213:Indomethacin / Q000494:pharmacology*; D008055:Lipids / Q000032:analysis; D008297:Male; D009093:Mucus / Q000032:analysis / Q000187:drug effects; D011506:Proteins / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains
D000897:Anti-Ulcer Agents; D002241:Carbohydrates; D004224:Diterpenes; D005227:Fatty Acids; D008055:Lipids; D011506:Proteins; D000431:Ethanol; C031049:geranylgeranylacetone; D007213:Indomethacin